课题基金 / 基金详情

DNA TOPOISOMERASES AS TARGET OF ACTION OF ANTICANCER DRUGS

DNA TOPOISOMERASES AS TARGET OF ACTION OF ANTICANCER DRUGS
DNA拓扑异构酶作为抗癌药物的作用靶点
批准号:
3838030
负责人:
Y POMMIER
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Y POMMIER的其他基金

相似基金

相关文献

中文摘要
翻译
DNA拓扑异构酶II(顶部2)是几个细胞的目标, 最有效的抗癌剂(多柔比星,依托泊苷[VP 16; VM-26], 米托蒽醌、安吖啶、椭圆形碱)。 因此,它是 抗癌药物开发的关键目标。 通过比较 VP-16发色团和椭圆藤碱的结构,我们合理地 设计了一种全合成的新药物-氮杂毒素。 发现阿扎毒素是一种具有独特DNA的活性前2位抑制剂 在纯化的TOP 2存在下的序列选择性。有趣的是,它 它不是DNA嵌入剂,它产生蛋白质连接的DNA断裂, 细胞 阿扎毒素及其抗肿瘤活性已申请专利 正在接受评估。 DNA拓扑异构酶I(top 1)也已成为一种重要的靶点, 自从发现喜树碱和几种抗癌药物 其衍生物是特定的顶级毒物, 喜树碱类似物显示出有希望的抗癌活性。 我们的一 目的是通过以下方法确定top 1抑制的分子机制: 喜树碱 我们最近使用前1位cDNA的研究表明, 喜树碱特异性地在切割位点处毒害TOP 1, 在它们的5 '末端有鸟嘌呤。 这一观察结果与我们的 光活化喜树碱诱导裂解的其它结果 尤其是鸟嘌呤 总之,这些数据支持我们以前的药物 药物诱导的拓扑异构酶抑制的堆积模型(Jessel等人, Nucleic Acids Res.1991;266:20418-23; Pomnival等人,Nucleic Acids Res. 1991;19:5973-80)。 分子药理学的另一种方法 喜树碱已经被用于开发和分析喜树碱抗性细胞。 我们发现了一个单点突变的前1个cDNA, 抗药性中国仓鼠细胞(Tanizawa和Pomyzawa,Cancer Res. 1991; 52:1848-54),表明突变区域可能是重要的 对于酶活性和喜树碱敏感性。
英文摘要
DNA topoisomerase II (top 2) is the cellular target of several among the most potent anticancer agents (Doxorubicin, etoposides [VP16; VM-26], mitoxantrone, amsacrine, ellipticines). For this reason, it is one of the key targets in anticancer drug development. By comparing the structures of the VP-16 chromophore and ellipticine, we have rationally designed azatoxin, a new drug which has been made by total synthesis. Azatoxin was found to be an active top 2 inhibitor with a unique DNA sequence selectivity in the presence of purified top 2. Interestingly, it is not a DNA intercalator, and it produces protein-linked DNA breaks in cells. A patent has been filed for azatoxin and its antitumor activity is being evaluated. DNA topoisomerase I (top 1) has also become an essential target for anticancer research since the discovery that camptothecin and several of its derivatives are specific top 1 poisons and that water-soluble camptothecin analogs exhibit promising anticancer activity. One of our goals is to identify the molecular mechanism(s) of top 1 inhibition by camptothecins. Our recent studies using top 1 cDNA demonstrate that camptothecin specifically poisons top 1 at the cleavage sites which have a guanine at their 5'-terminus. This observation is consistent with our other results that photoactivated camptothecin induces cleavage specifically at guanines. Together, these data support our previous drug stacking model for drug-induced topoisomerase inhibition (Jaxel et al., Nucleic Acids Res. 1991;266:20418-23; Pommier et al., Nucleic Acids Res. 1991;19:5973-80). Another approach to the molecular pharmacology of camptothecin has been to develop and analyze campothecin-resistant cells. We are finding a single point mutation in the top 1 cDNA from drug-resistant Chinese hamster cells (Tanizawa and Pommier, Cancer Res. 1991; 52: 1848-54), indicating that the mutated region might be important for both enzymatic activity and camptothecin sensitivity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PROTEIN-ASSOCIATED DNA BREAKS AS INDICATOR OF TOPOISOMERASE INHIBITION
  • 批准号:
    3916548
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Y POMMIER
  • 依托单位:
TOPOISOMERASE II AS TARGET OF ACTION OF ANTICANCER DRUG
  • 批准号:
    3939497
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Y POMMIER
  • 依托单位:
PHARMACOLOGY OF THE HIV VIRAL DNA
  • 批准号:
    3838171
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Y POMMIER
  • 依托单位:
PROTEIN-ASSOCIATED DNA BREAKS AS INDICATOR OF TOPOISOMERASE INHIBITION
  • 批准号:
    3752315
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Y POMMIER
  • 依托单位:
海外基金